RoslinCT vs WuXi Biologics: CDMO Comparison
How does RoslinCT compare to WuXi Biologics for CAR-T manufacturing?
Side-by-side comparison of RoslinCT and WuXi Biologics on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- RoslinCT has FDA inspections on record (1); WuXi Biologics does not yet appear in the FDA inspection database.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- WuXi Biologics holds 3 active EMA GMP certificates; RoslinCT does not appear in EudraGMDP.
On a 13-modality CDMO landscape, both RoslinCT and WuXi Biologics qualify as CAR-T manufacturers; WuXi Biologics carries the higher composite Signal Score for CAR-T programs in this comparison.
What to evaluate for CAR-T programs
Both RoslinCT and WuXi Biologics qualify as CAR-T CDMOs. When choosing between them for CAR-T programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Vector supply
CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost.
Autologous logistics & turnaround
Autologous CAR-T lives or dies on vein-to-vein time and chain-of-identity. Evaluate scheduling, apheresis handling, and cryo-logistics.
Closed, scalable processing
Closed and automated platforms reduce contamination risk and support parallel patient slots. Ask about cleanroom grade and concurrent-batch capacity.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
Frequently asked: RoslinCT vs WuXi Biologics
How does RoslinCT compare to WuXi Biologics for CAR-T manufacturing?
On CDMO Signal's composite Signal Score, RoslinCT is 80/100 and WuXi Biologics is 83/100; RoslinCT has 1 FDA inspection on record vs 0 for WuXi Biologics; European coverage is 1 active EMA+MHRA certificate for RoslinCT vs 4 for WuXi Biologics. Both are tracked in the CDMO Signal directory as CAR-T CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, RoslinCT or WuXi Biologics?
Both RoslinCT and WuXi Biologics maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. RoslinCT has 1 FDA inspection on record; WuXi Biologics has 0.
How do RoslinCT and WuXi Biologics compare on European GMP coverage?
RoslinCT holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. WuXi Biologics holds 3 active EMA GMP certificates and 1 MHRA / UK certificate. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for CAR-T manufacturing — RoslinCT or WuXi Biologics?
Both RoslinCT and WuXi Biologics are tagged as CAR-T CDMOs in our directory, so both are credible options for CAR-T programs. The most important differentiator for CAR-T selection is typically vector supply: CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
RoslinCT carries a Signal Score of 80/100 and WuXi Biologics carries 83/100 — essentially tied for WuXi Biologics. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →